Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Chelstrom

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 10, 1995
Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cellsD E Myers, X Jun, K G Waddick, et al.
Blood|May 1, 1992
In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiencyF M Uckun, C Manivel, D Arthur, et al.
Blood|May 15, 1992
In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemiaF M Uckun, L M Chelstrom, J D Irvin, et al.
Blood|June 1, 1993
Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiencyF M Uckun, J R Downing, R Gunther, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1996
Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinosideY Messinger, Y Yanishevski, V I Avramis, et al.
Blood|May 15, 1995
In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cellsF M Uckun, C F Stewart, G Reaman, et al.
Science (New York, N.Y.)|February 10, 1995
Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinasesF M Uckun, W E Evans, C J Forsyth, et al.
Leukemia & Lymphoma|June 1, 1996
Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxinR Gunther, L M Chelstrom, H R Wendorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factorF M Uckun, R K Narla, T Zeren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptorJ P Perentesis, R Gunther, B Waurzyniak, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|October 10, 1995
Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cellsD E Myers, X Jun, K G Waddick, et al.
Blood|May 1, 1992
In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiencyF M Uckun, C Manivel, D Arthur, et al.
Blood|May 15, 1992
In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemiaF M Uckun, L M Chelstrom, J D Irvin, et al.
Blood|June 1, 1993
Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiencyF M Uckun, J R Downing, R Gunther, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1996
Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinosideY Messinger, Y Yanishevski, V I Avramis, et al.
Blood|May 15, 1995
In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cellsF M Uckun, C F Stewart, G Reaman, et al.
Science (New York, N.Y.)|February 10, 1995
Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinasesF M Uckun, W E Evans, C J Forsyth, et al.
Leukemia & Lymphoma|June 1, 1996
Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxinR Gunther, L M Chelstrom, H R Wendorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factorF M Uckun, R K Narla, T Zeren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptorJ P Perentesis, R Gunther, B Waurzyniak, et al.
Pageof 4